Revvity stock forecast 2027–2029
MyStockButler's October 2026 analysis: The weighted forecast points to $78.75 in October 2027 and $95.23 in October 2029, including dividends. It hinges on earnings recovery and better margins.
Where could Revvity's shares be by 2029?
The weighted forecast points to $78.75 in October 2027 (−50%) and $95.23 in October 2029 (−39%), including dividends, and hinges on earnings recovery and better margins.
The forecast assigns a 25% probability to the bear case and 50% to the base case. The bull case has a 25% probability. On November 3, 2026, imaging orders must become shipments, revenue, and repeat reagent demand; Signals revenue and the $25 million Genomics England outlook must hold. Genomics England is a UK organization that studies genes and supports health research. At Investor Day on November 13, 2026, GMP capacity, customer qualification milestones, expected revenue, and required investment matter. GMP means rules for making medicines and diagnostic products consistently and safely. By the expected China sale closing at the end of 2027, growth in the remaining businesses must offset lost revenue and profit.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 46.83 (-70 %) | 42.14 (-73 %) | 41.23 (-74 %) |
| Base | 50 % | 80.18 (-49 %) | 84.33 (-47 %) | 88.94 (-43 %) |
| Bull | 25 % | 107.82 (-32 %) | 134.71 (-15 %) | 161.83 (+3 %) |
| Weighted | 100 % | 78.75 (-50 %) | 86.38 (-45 %) | 95.23 (-39 %) |
What this means. The weighted row is the probability-based average of the three cases, so it can be far below today's share price even though the bull case rises.
How much cash does Revvity really make?
Stock compensation requires a further adjustment. Revvity recorded $22.8 million of stock pay in 2025. Deducting it produces analytical “real free cash flow” of $492.6 million, because issuing shares gives employees a claim on the company even when no immediate cash leaves.
| 2025 | 2024 | 2023 | Jan 2023 | Jan 2022 | |
|---|---|---|---|---|---|
| Cash from operations | 588,956 | 664,955 | 279,387 | 672,500 | 1,330,184 |
| − Capital spending | 73,522 | 86,648 | 81,368 | 85,632 | 86,020 |
| = Free cash flow | 515,434 | 578,307 | 198,019 | 586,868 | 1,244,164 |
| − Stock pay | 22,847 | 37,809 | 41,410 | 51,518 | 29,675 |
| = Real free cash flow | 492,587 | 540,498 | 156,609 | 535,350 | 1,214,489 |
What this means. The company's free cash flow is shown as 66 thousand dollars higher in 2025 only because of rounding, not because it counted extra cash.
What does an investor pay for Revvity?
P/E means price divided by earnings per share. Trailing P/E uses the last twelve months; forward P/E uses an estimate for the next twelve. Their wide gap makes normalization important. Imagine a shop whose previous year was unusually weak and whose next year is expected to be ordinary. The same price produces a high trailing multiple and a lower forward multiple, but the forecast must still prove realistic.
| Today (Oct 24, 2026) | |
|---|---|
| Share price | 158.77 |
| P/E, last 12 months (calculated) | 75.2x |
| P/E, next 12 months (calculated) | 26.9x |
| Free cash flow yield (calculated) | 2.9% |
| Real free cash flow yield (calculated) | 2.8% |
What this means. The price-to-earnings number drops from 75.2 using past profit to 26.9 using expected future profit, so the lower number depends on analysts being right.